A potential COVID-19 treatment has yielded promising results in clinical trials: Dexamethasone helps reduce mortality in cases of severe respiratory complications,media reported. The drug is a low-cost steroid drug that is commonly used to treat inflammation. The UK government’s chief scientific adviser has described the drug’s potential as a “breakthrough development” in the treatment of the new coronavirus.
The dexamethasone trial was carried out in the UK as part of the RECOVERY trial, which aims to explore a range of potential COVID-19 treatments. Of the more than 11,500 patients who participated in the trial, 2,104 were randomly orally or injected with dexamethasone. They received 6 milligrams of the drug daily by oral or intravenous injection for ten days. The control group was 4,321 patients receiving standard care.
In patients who need ventilation, the drug can reduce the number of deaths by one-third. For those who receive only oxygen, Dexamethason has reduced the death toll by a fifth. THOSE WITH COVID-19 WHO DID NOT REQUIRE RESPIRATORY INTERVENTION DID NOT SHOW THE BENEFITS OF STEROIDS. This is an important discovery made by the RECOVERY team. Part of the advantage of Dexamethason is that it is affordable. In the U.S., the average retail price is less than $50, but patients get the drug on a doctor’s prescription — for a course of treatment for as little as $8.
Dexamethasone is the first drug to be shown to improve COVID-19 survival. Peter Horby, professor of emerging infectious diseases at The University of Oxford’s Nuffield School of Medicine and one of the lead researchers on the trial, said of the findings. “This is a very welcome result. For those who are seriously ill who need oxygen-absorbing treatment, the survival benefits are obvious and significant, so dexamethasone should now be the standard treatment for these patients. The low price of dexamethasone, a ready-made drug that can be used immediately, saving lives around the world. “
“Since the emergence of COVID-19 six months ago, people have been looking for treatments that can improve survival rates, especially in patients with serious conditions. Martin Landray, professor of medicine and epidemiology at the Department of Population Health at The Nuffield School of Medicine, Oxford, said of the study. “These preliminary results from the RECOVERY trial are very clear – dexamethasone can reduce the risk of death in patients with severe respiratory complications. “